Puma Bio FDA Advisory Panel Live Blog - TheStreet
Puma Biotechnology says its breast cancer therapy included in two key NCCN updates | Seeking Alpha
Puma Biotechnology
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Surging
Puma Biotechnology Reports Third Quarter 2022 Financial Results | Business Wire
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology
Puma Biotechnology Careers | Wellfound (formerly AngelList Talent)
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology Inc
Analyst Rating: Will Puma Biotechnology Inc (PBYI) Stock Lead the Market?
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity - Market Exclusive
JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
